Combination of gefitinib and AZD6244 overcomes acquired gefitinib resistance and enhances anticancer effect in lung adenocarcinoma cells harboring an activating EGFR mutation
碩士 === 國立陽明大學 === 藥理學研究所 === 99 === Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are very effective treatment for patients with non-small cell lung cancer (NSCLC) with EGFR TK domain mutations. However, acquired resistance to EGFR-TKIs dev...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2011
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/24800095830895726361 |